cnbc.com
MariTide Trial Results and Market Reaction
Amgen's weight loss drug, MariTide, shows bone density loss in early trials, causing market uncertainty.
English
United States
HealthInvestmentMarket AnalysisPharmaceuticalsClinical Trials
AmgenCantor FitzgeraldJefferiesBmoNovo Nordisk
Olivia BrayerMichael YeeEvan Seigerman
- How did the market react to the additional data on MariTide?
- The bone density loss is dose-dependent, meaning higher doses correlated with greater loss. While some analysts view this as a potential safety risk, others suggest this is a typical early effect of weight loss drugs that normalizes over time.
- What is Amgen's response and the overall outlook for MariTide?
- Amgen is aware of the bone density concerns and is monitoring the situation closely. They have communicated with analysts and believe that the effects will normalize over time, although the market reaction suggests significant investor uncertainty.
- How does MariTide's mechanism of action differ from its competitors?
- MariTide's mechanism differs from competitors like Wegovy and Mounjaro; it blocks a gut hormone receptor (GIPR) while activating another (GLP-1). This unique mechanism may contribute to the observed bone density changes.
- What were the findings of the early-stage trial on Amgen's MariTide?
- Amgen's experimental weight loss injection, MariTide, showed a 4% bone mineral density loss in a phase one trial's highest dosage group. This led to a 7% drop in Amgen shares, though some analysts believe it's an overreaction and more data is needed.
- What are the differing opinions of analysts on the significance of the bone density data?
- Analysts are divided; some see potential safety concerns and market overreaction, while others consider the bone density changes a temporary effect not indicative of a major risk. The full Phase 2 trial results, expected later this year, will provide more clarity.